Skip to main content
Fig. 6 | Journal for ImmunoTherapy of Cancer

Fig. 6

From: Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Fig. 6

Reduction of PD-1 expression by CD8+ T cells after RAM-containing therapies. a Representative flow cytometry from PBMCs and TILs both pre- and post-treatment in the same patient. This patient was treated with RAM and CPT-11 and attained PD after 6 weeks of treatment. The PD-1 expression by CD8+ T cells in TILs was especially elevated as compared to that in PBMCs. PD-1 expression by CD8+ T cells were decreased after treatment (from 62.6 to 32.9%) in TILs, while these cells were not decreased in PBMCs (from 3.59 to 5.51%). b Kinetic changes in PD-1 expression by CD8+ T cells. The PD-1 expression by CD8+ T cells in TILs was significantly decreased after RAM-containing therapies (54.99 ± 19.06% vs. 39.23 ± 17.15%; P < 0.01), whereas no significant difference was observed in PD-1 expression by CD8+ T cells in PBMCs (8.25 ± 6.05% vs. 7.47 ± 5.18%; P = 0.33). The averages were used if more than one samples at post-treatment were available. n.s., not significant

Back to article page